GHKCU50mg+KPV10mg

GHK-Cu 50 mg + KPV 10 mg Research Blend Guide

GHK-Cu KPV blend is a two-peptide research formulation containing 50 mg GHK-Cu and 10 mg KPV, designed for studies of tissue-response signaling, inflammatory-pathway modulation, extracellular-matrix biology, and formulation behavior. It combines GHK-Cu (the copper complex of glycyl-L-histidyl-L-lysine) with KPV (Lys-Pro-Val), the C-terminal tripeptide sequence associated with alpha-melanocyte-stimulating hormone. The components have distinct research histories: GHK-Cu has been investigated in models of matrix remodeling, cell migration, and copper-dependent redox biology, whereas KPV has been examined in cellular and animal inflammation models. This product is supplied for laboratory research, analytical development, and in-vitro or preclinical investigation only; it is not a medicine, cosmetic finished product, food, supplement, or treatment.

The value of a blend is a research question, not a clinical conclusion. Combining two small peptides may allow a laboratory to compare component-specific and combined effects under controlled conditions, but it does not establish synergy, safety, stability after mixing, pharmacokinetics, or a therapeutic outcome. Appropriate controls, validated analytical methods, and ethics-approved protocols remain essential.

Identity, composition, and physicochemical considerations

• GHK-Cu component: glycyl-L-histidyl-L-lysine coordinated with copper(II); peptide sequence Gly-His-Lys (GHK).
• KPV component: Lys-Pro-Val; a three-amino-acid C-terminal alpha-MSH-related sequence.
• Nominal blend content: 50mg GHK-Cu plus 10mg KPV per labeled unit.
• Form: lyophilized research material. The appearance, color, and cake morphology may vary with lot, buffer, and copper coordination state.
• Molecular-weight reporting: because this is a blend rather than one molecular entity, verify component identity and lot-specific mass data on the certificate of analysis (COA).
• Purity and identity: assess with validated HPLC/UPLC and mass-spectrometric methods; do not infer blend purity from visual appearance.

GHK-Cu chemistry deserves particular attention in experimental design. Copper coordination can be sensitive to pH, competing ligands, buffers, chelators, proteins, and container-contact materials. KPV is a small, polar tripeptide whose behavior may be influenced by pH, ionic strength, adsorption to surfaces, and enzymatic degradation. A blend should therefore be treated as a formulation under test: researchers should characterize it under their own matrix, temperature, and time-course conditions rather than extrapolating from a single-component experiment.

Research mechanisms under investigation

1. Copper-peptide coordination and redox context

GHK binds copper through its peptide residues and has been studied as a model for copper-peptide interactions in extracellular and cellular environments. Copper is an essential cofactor in many biological processes, yet unbound or poorly controlled copper can also alter oxidation-reduction behavior. In research settings, the relevant question is often not simply whether GHK-Cu is present, but how the complex behaves in the selected buffer, medium, and protein environment.

2. Extracellular-matrix and connective-tissue signaling models

Published GHK/GHK-Cu literature has described changes in fibroblast-associated processes, collagen-related expression, metalloproteinase balance, and cell migration in experimental systems. Such observations make the component useful for hypothesis-driven work on matrix turnover and repair signaling. They do not demonstrate that a research material repairs tissue in people or animals, and results can vary substantially by model, concentration, exposure time, and assay endpoint.

3. Inflammatory transcription-pathway studies

KPV has been evaluated in cell and murine inflammation models. A widely cited 2007 study reported PepT1-mediated uptake and reductions in NF-kappaB and MAP-kinase signaling readouts in experimental intestinal epithelial and immune-cell systems. A separate murine colitis study reported reduced inflammatory findings in those models. These are preclinical observations, not dosing instructions or evidence of approved clinical use.

4. Peptide transport and cellular uptake questions

Short peptides may access cells through transporter-mediated, endocytic, or matrix-associated routes that depend on cell type and experimental conditions. KPV has been studied in the context of the peptide transporter PepT1; GHK-Cu has a different coordination and trafficking context. The combination supports comparative experiments in which uptake, intracellular localization, peptide recovery, or degradation products are measured separately for each component.

5. Cytokine and mediator panels

Researchers studying stimulated immune, epithelial, or skin-relevant cell systems may evaluate cytokines, chemokines, NF-kappaB reporters, reactive-oxygen-species indicators, and viability endpoints. The appropriate panel should be chosen before the experiment, with vehicle, positive-control, and individual-component arms. Claims about anti-inflammatory activity should be limited to the measured model and endpoint.

6. Formulation compatibility and stability

This blend is also suitable for analytical-development questions: dissolution behavior, adsorption loss, stability over time, chromatographic separation, and copper-complex integrity. A stability-indicating HPLC method, supported where appropriate by LC-MS, is more informative than relying on clarity or color. Investigators should document the exact solvent, pH, container type, freeze-thaw history, and sampling time points.

Potential research applications

Cell-culture pathway research: establish concentration-response curves in relevant cell lines, then quantify viability and pathway endpoints before interpreting a mechanistic effect. Because copper-containing complexes can behave differently in serum-containing and serum-free media, use matched controls.

Matrix-remodeling assays: fibroblast migration, collagen-associated gene-expression panels, matrix-metalloproteinase assays, and extracellular-matrix deposition models can be used to examine research hypotheses related to GHK-Cu. These assays require careful normalization for cell number and cytotoxicity.

Inflammation-model comparisons: KPV literature has motivated experiments involving cytokine-stimulated epithelial or immune cells. A combined-material study should retain separate GHK-Cu and KPV arms, since a blend cannot by itself identify the component responsible for an observed signal.

Delivery and analytical research: the distinct peptide masses and chemical properties make this blend useful for method-development work, including separation, recovery, and degradation profiling. Any delivery-platform experiment should remain within institutional approvals and should not be extrapolated to consumer or clinical use.

Product specification

Product	GHK-Cu 50mg + KPV 10mg research blend
Components	GHK-Cu (Gly-His-Lys copper complex) and KPV (Lys-Pro-Val)
Nominal content	50mg GHK-Cu + 10mg KPV per labeled unit
Appearance	Lyophilized material; inspect each unit and refer to its COA
Identity / purity control	Lot-specific HPLC/UPLC and mass-spectrometric verification
Solubility	Must be established in the selected research solvent and matrix
Storage	Store unopened material according to the label and COA, protected from moisture and light
Intended use	Research and analytical use only; not for human or animal administration

Laboratory handling and reconstitution considerations

Use an aseptic, documented laboratory workflow appropriate to the experiment. Before preparing working solutions, review the COA and establish a written plan that specifies the required concentration, solvent compatibility, container material, pH range, temperature, and sampling schedule. Do not assume that a solvent suitable for one peptide or a historical protocol is suitable for this blend. Copper-binding ligands, strong chelators, and some buffer systems may change the GHK-Cu complex; researchers should test compatibility rather than infer it.

For analytical studies, prepare only the amount needed for a validated experiment, mix gently, and record the solution appearance and preparation time. Confirm concentration with a suitable method where quantitative accuracy matters. Use aliquots to minimize repeated freeze-thaw cycles, protect light-sensitive samples when appropriate, and maintain an auditable chain of custody. This page intentionally does not provide administration routes or dose recommendations: this product is not approved for human or veterinary use and must not be used for consumption or treatment.

Frequently asked questions

What is this blend?

It is a research formulation containing GHK-Cu and KPV in a labeled 50mg:10mg ratio. GHK-Cu is a copper-coordinated tripeptide and KPV is a short alpha-MSH-related tripeptide. The blend is intended for laboratories investigating peptide chemistry, cell signaling, matrix biology, inflammatory-model readouts, or analytical behavior. It is not a finished drug, injectable product, dietary supplement, or cosmetic product.

Does the combination prove synergy?

No. A combination may be studied for complementary or interacting effects, but synergy must be demonstrated in the specific model using predefined endpoints and appropriate single-component and vehicle controls. Data from GHK-Cu or KPV alone cannot establish that the combined material has a predictable or superior effect in another assay, species, or setting.

What dose should be used?

Hanpro Peptides does not provide dose recommendations for people or animals. Researchers should determine concentration ranges through institutionally approved, model-specific pilot studies and follow relevant laboratory safety, ethics, and regulatory requirements. Any reported concentration should be tied to a defined in-vitro or preclinical protocol, not translated into a self-administration instruction.

How should researchers assess quality?

Review the lot-specific COA, then use fit-for-purpose methods such as HPLC/UPLC and mass spectrometry to confirm the material in the receiving laboratory when required. For a copper-containing blend, a stability-indicating method and recovery study can be especially useful. Appearance alone cannot confirm identity, purity, concentration, sterility, or biological activity.

Can it be combined with other compounds?

Only as part of a justified and controlled research design. Evaluate compatibility, analytical interference, and safety before mixing. Copper coordination and peptide stability can be altered by buffers, chelators, proteins, surfactants, and other actives. Use separate controls so that any observed result can be attributed appropriately.

How should unopened and prepared material be stored?

Follow the storage conditions printed on the product label and COA. Keep lyophilized material dry and protected from light. Once a research solution has been prepared, establish its stability for the actual solvent, concentration, container, and temperature used; do not rely on a generic storage interval for every experiment.

Is this product legal for therapeutic use?

No therapeutic claim is made. This material is sold for lawful research and analytical use only. It is not FDA-approved to diagnose, treat, cure, or prevent disease, and it is not intended for human or animal consumption. The purchasing institution and investigator are responsible for ensuring that procurement, storage, and use comply with applicable laws and institutional policies.

Related research products

• GHK-Cu – single-component copper-peptide research material.
• KPV – single-component Lys-Pro-Val research peptide.
• GLOW – a multi-peptide blend for comparative formulation research.
• BPC 157 – a separate peptide commonly used in preclinical tissue-response studies.
• TB500 – a thymosin-beta-4-related research product.
• AHK-Cu – a related copper-binding tripeptide for comparative analytical work.
• KLOW – a broader multi-component blend for formulation comparisons.
• Cartalax – an Ala-Glu-Asp tripeptide research material.

Selected research references

• Pickart L, Margolina A. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID: 18644225.
• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID: 18061177.
• Diller RB, Tabor AJ. The Role of the Extracellular Matrix in Wound Healing: A Review. Biomimetics. 2022. PMID: 35892357.
• Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016. PMID: 27458604.

Quality assurance and research-use disclaimer

Hanpro Peptides uses lot-specific analytical documentation to support identity and purity review. Researchers should request and retain the applicable COA and independently verify suitability for their experimental system. This material is supplied for laboratory research and analytical purposes only. It is not for human or animal consumption, diagnosis, treatment, or prevention of disease. It has not been evaluated or approved by the FDA for therapeutic use. Investigators are solely responsible for lawful, ethical, and properly controlled use.